Cellares has successfully raised $355 million in funding to advance its cancer treatment technology. The funding round aims to support the development of innovative cell therapy methods to combat blood cancer.
Cellares has successfully raised $355 million in funding to advance its cancer treatment technology. The funding round aims to support the development of innovative cell therapy methods to combat blood cancer.
03/24/25, 12:04 PM
Location
san franciscoMoney raised
$355 million
Industry
biotechnology
manufacturing
Cellares, a biotech startup based in Bridgewater, N.J., has secured $355 million in funding to further its groundbreaking approach to cancer treatment. The company specializes in developing customized cell therapy solutions that utilize patients' own white blood cells. By advancing their technology, Cellares aims to overcome the challenges of producing these therapies at scale. This significant funding will enhance their capabilities in an important and evolving area of medical research.
Company Info
Location
345 allerton ave
san francisco, california, united states
Additional Info
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is both developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company’s Cell Shuttle integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers true walk-away, end-to-end automation. Cell Shuttles will be deployed in Cellares’ Smart Factories around the world to meet total patient demand for cell therapies at global scale. Partnering with Cellares enables academics, biotechs, and pharma companies to accelerate drug development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand.